SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Lorraine Hansberry — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLorraine Hansberry
Date of birth1930-05-19
IdentifiersMRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158
Document date1963-08-10
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review after six cycles: restaging results and the decision for surgery. [S]

History of Present Illness

Ms. Hansberry returns two weeks after her sixth and last cycle before surgery. The diarrhea after cycle 5 settled within two days with loperamide, fluids and potassium, and with irinotecan reduced for cycle 6 she had only two loose stools. The restaging CT four days ago shows the tumor smaller and less contact with the vein, with no spread, and the tumor board recommends surgery; she met the surgeon and has chosen to go ahead. The interim CT ordered before cycle 5 was never scheduled. The cold-induced tingling is fading and her fingertips feel almost normal. Pain is 1 out of 10 and she takes oxycodone once every few days. She walks 30 minutes a day to prepare for surgery. Home fasting glucose is 115 to 135 mg/dL. She has had no bleeding on apixaban. She has written most mornings this month. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentSix cycles of modified FOLFIRINOX; irinotecan reduced for cycle 6 after grade 2 diarrhea
Restaging CTMass 2.1 cm from 3.1 cm; vein contact about 150 degrees; no arterial contact; no metastases
DecisionPancreaticoduodenectomy with vein resection in two weeks
EffectsDiarrhea resolved; neuropathy fading
PreparationWalking 30 minutes daily; protein supplements

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; weight 54.2 kg; no fever
GastrointestinalNegativeDiarrhea resolved; stools formed; no nausea; no black stools
NeurologicalPositiveFingertip tingling fading; no weakness
Hematologic and lymphaticNegativeNo bleeding or bruising on apixaban
RespiratoryNegativeNo cough or breathlessness
PsychiatricPositiveHopeful and nervous about surgery; PHQ-9 6; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route1963-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route1963-04-24 to 1963-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route1963-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route1963-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route1963-05-04 to 1963-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route1963-05-18 to 1963-07-13completedS
Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6Day 1 of cycle 6Intravenous route1963-07-27 to 1963-07-27completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route1963-05-20 to 1963-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route1963-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route1963-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route1963-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route1963-06-29 to 1963-08-21completedS
Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days40 mEq today, then 20 mEq daily for three daysOral route1963-07-16 to 1963-07-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1963-08-10Body height163cmS
1963-08-10Body weight54.2kgS
1963-08-10Body mass index (BMI) [Ratio]20.4kg/m2S
1963-08-10Systolic blood pressure112mm[Hg]S
1963-08-10Diastolic blood pressure72mm[Hg]S
1963-08-10Heart rate80/minS
1963-08-10Respiratory rate16/minS
1963-08-10Body temperature36.6CelS
1963-08-10Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1963-08-10Hemoglobin [Mass/volume] in Blood10.9g/dL12-15.5 g/dLLowS
1963-08-10Leukocytes [#/volume] in Blood by Automated count7.810*3/uL4-11 10*3/uLNormalS
1963-08-10Neutrophils [#/volume] in Blood by Automated count4.910*3/uL1.5-7.7 10*3/uLNormalS
1963-08-10Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS
1963-08-10Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1963-08-10Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1963-08-10Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
1963-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M107mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1963-08-10Glucose [Mass/volume] in Serum or Plasma124mg/dL70-99 mg/dLHighS
1963-08-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1963-08-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-35 U/LNormalS
1963-08-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma98U/L35-104 U/LNormalS
1963-08-10Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1963-08-10Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
1963-08-10Hemoglobin A1c/Hemoglobin.total in Blood7%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
1963-08-10Cancer Ag 19-9 [Units/volume] in Serum or Plasma41U/mL<=35 U/mLHighS
1963-08-10INR in Platelet poor plasma by Coagulation assay1{INR}0.8-1.2NormalS
1963-08-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1963-08-10Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S

Physical Exam

Vital signs recorded on 1963-08-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 54.2 kg; blood pressure 112/72, pulse 80
EyesNo icterus
AbdomenSoft, non-tender; no mass; port site clean
NeurologicalLight touch at the fingertips almost normal; vibration and reflexes normal
ExtremitiesNo leg swelling
PsychiatricCalm, focused, asks about recovery time for writing

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPactiveconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolvedresolvedconfirmed K52.1S — Synthetic treatment effect; not a historical claim.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingRestaging CT after chemotherapy before surgeryAfter completing therapy before surgeryUp to dateFour days ago: partial response; vein contact about 150 degrees; no arterial contact; no metastases
ImagingInterim restaging CTEvery two months during chemotherapy before surgeryDeferredA deviation: the interim CT ordered at cycle 4 was never scheduled. No harm resulted: CA 19-9 kept falling and today's CT shows a response without progression. Corrective action: the nurse navigator now tracks every imaging order to a booked date
LaboratoryCA 19-9At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six monthsCompleted today41 U/mL, from 210 at cycle 4 and 486 at diagnosis
LaboratoryBlood count with neutrophils and plateletsBefore surgeryCompleted todayHemoglobin 10.9 g/dL, white cells 7.8, neutrophils 4.9, platelets 176
LaboratoryKidney and liver function, electrolytes and albumin before surgeryWithin 30 days before surgeryCompleted todaySodium 138, potassium 4.1 mmol/L; creatinine 0.76 mg/dL, eGFR 107; ALT 24, AST 26, alkaline phosphatase 98 U/L, bilirubin 0.5 mg/dL; albumin 3.6 g/dL
LaboratoryINR before surgeryBefore surgeryCompleted today1.0
ReferralPancreatic tumor board and surgical oncologyAfter restagingUp to dateTumor board three days ago and surgical consultation: resection recommended and accepted
Medication safetyAnticoagulation around surgeryBefore and after surgeryCompleted todayApixaban stopped three days before surgery; enoxaparin 40 mg daily for four weeks after it
ExaminationOxaliplatin neuropathy: symptoms and examinationAt each visit after oxaliplatinCompleted todayGrade 1 and fading
SurveyPain score and opioid reviewEach visitCompleted todayPain 1 out of 10; oxycodone once every few days
Self-managementWeight, nutrition and enzyme replacementEach visitCompleted todayWeight 54.2 kg, 2 percent below the weight at diagnosis; protein supplements and walking to prepare for surgery
LaboratoryGlucose and home readingsEach visit and before each cycleCompleted todayGlucose 124 mg/dL
LaboratoryA1cEvery three months while treatment changesCompleted today7.0%, from 6.6% at the first visit
ExaminationDilated eye examination and urine albumin-to-creatinine ratioAt diagnosis of diabetes, then yearlyDeferredStill outstanding (see the deviation at cycle 4); booked with the visit after surgery
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 6

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Surgery in two weeks. Primary care review about six weeks after surgery with the pathology. Call for fever, bleeding, or leg swelling before then. Next scheduled visit 1963-10-05: six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery. [S]